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A commentary on
Ultraviolet-inactivated vaccinia virus (VV) 
in a multi-envelope DNA-VV-protein 
(DVP) HIV-1 vaccine protects macaques 
from lethal challenge with heterologous 
SHIV
by Jones BG, Sealy RE, Zhan X, Freiden 
PJ, Surman SL, Blanchard JL, Hurwitz JL. 
(2012). Vaccine 30:3188–95. doi: 10.1016/j.
vaccine.2012.03.001 
The title and conclusions of the study 
recently published by Jones et al. (1) con-
cluded that monkeys were protected from 
dying from a form of simian-human immu-
nodeficiency virus (SHIV) by an psoralen- 
and ultraviolet-inactivated vaccinia virus in 
a multi-envelope DNA-VV-protein (DVP). 
However, the findings in the study are more 
equivocal than indicated by the title because 
the effectiveness of the modified vaccinia 
virus was not decisively demonstrated.
With regard to the effectiveness in reduc-
ing SHIV virus levels, the only significant 
effect was in reducing the peak viral loads, 
which was a fleeting condition around 
the second week after virus exposure. The 
more important virus levels are those over 
the long term because of the slow and pro-
gressive nature of SHIV. As the authors 
indicated, and which also is obvious from 
viewing the charts in Figure 4 from the 
above study, there was no significant action 
by DVP in the third through 17th week.
With regard to effectiveness of DVP 
in preventing reduction of T helper cells, 
the data in the study show that, with the 
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exception of one case (monkey CA12), the 
envelope components alone (DNA and 
protein) appeared to offer protection that 
was comparable to the envelope compo-
nents plus the psoralen- and ultraviolet-
inactivated vaccinia virus (Figure 5). The 
idea that the envelope vehicle without the 
vaccinia virus might have been as effective 
as regular live vaccinia virus or DVP was 
not addressed.
With regard to preventing death, the 
findings do offer weak evidence for the 
notion that vaccinia virus delivered by any 
of the three methods (live, late, DVP, or pos-
sibly DNA/protein alone) have a protective 
effect because 66% of the unvaccinated cases 
died as compared to 6% of the vaccinated. 
The problem is that the statistical signifi-
cance of the above difference in protective 
effect was based on Fisher’s Exact Test. If 
any cell has fewer than two or three cases, 
as established by Hanley and Lippman-
Hand (2), there were zero cases for the cell 
for VV-protected cases that did not survive. 
A better statistical method for studying 
survival is Kaplan–Meier estimate which is 
designed for studying survival rates. When 
the data from the graphs in the figures of the 
above article were digitized and analyzed by 
the Kaplan–Meier method, the results are 
not statistically significant at p < 0.05 level. 
Thus, the conclusion that DVP had a pro-
tective effect against death is not supported 
at this time due to absence of statistical 
significance.
The study has much value because of the 
phenomenal amount of challenging bio-
chemical and immunological work using a 
wide array of methods which each require 
expertise, the obvious passion for the devel-
opment of a potent, readily manufactured 
vaccine against HIV, the new approach sug-
gested of activating lymphocytes of many 
types, and other strengths. Nevertheless, 
due to over interpretation of the data, the 
main conclusion that DVP has a protective 
effect, and the implication in the title that 
the actions of DVP are different from the 
envelope or vaccinia virus by itself, are not 
warranted.
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